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Abstract
Classical swine fever is a highly contagious disease of swine caused by classical swine fever virus, an OIE list A
pathogen. Epitope-based vaccines is one of the current focuses in the development of new vaccines against
classical swine fever virus (CSFV). Two B-cell linear epitopes rE2-ba from the E2 glycoprotein of CSFV, rE2-a
(CFRREKPFPHRMDCVTTTVENED, aa844-865) and rE2-b (CKEDYRYAISSTNEIGLLGAGGLT, aa693-716), were constructed
and heterologously expressed in Escherichia coli as multiple epitope vaccine. Fifteen 6-week-old specified-
pathogen-free (SPF) piglets were intramuscularly immunized with epitopes twice at 2-week intervals. All epitope-
vaccinated pigs could mount an anamnestic response after booster vaccination with neutralizing antibody titers
ranging from 1:16 to 1:256. At this time, the pigs were subjected to challenge infection with a dose of 1 × 10
6
TCID50 virulent CSFV strain. After challenge infection, all of the rE2-ba-immunized pigs were alive and without
symptoms or signs of CSF. In contrast, the control pigs continuously exhibited signs of CSF and had to be
euthanized because of severe clinical symptoms at 5 days post challenge infection. The data from in vivo
experiments shown that the multiple epitope rE2-ba shown a greater protection (similar to that of HCLV vaccine)
than that of mono-epitope peptide(rE2-a or rE2-b). Therefore, The results demonstrated that this multiple epitope
peptide expressed in a prokaryotic system can be used as a potential DIVA (differentiating infected from vaccinated
animals) vaccine. The E.coli-expressed E2 multiple B-cell linear epitopes retains correct immunogenicity and is able
to induce a protective immune response against CSFV infection.
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1. Introduction
Classical swine fever (CSF) or hog cholera is a highly
infectious viral disease included in the list of diseases
notifiable to the OIE (http://www.oie.int). It affects
domestic and wild pigs and is considered to be one of
the most devastating diseases for the pig industry
throughout the world from both the economic and sani-
tary point of view [1,2]. CSF virus (CSFV), the etiologi-
cal agent of CSF, is an icosahedral and enveloped
positive strand RNA virus that belongs to the Pestivirus
genus of the Flaviviridae family [3-5]. Pestivirus RNA
contains a single large open reading frame (ORF)
flanked by two untranslated regions (UTRs). The ORF
encodes a polyprotein of about 3900 amino acids that in
infected cells is processed by cellular as well as viral
proteases to yield four structural (C, Erns, E1, E2) and
eight nonstructural proteins (Npro, P70, NS2, NS3,
NS4A, NS4B, NS5A, NS5B) [6-8].
E2 is the essential protein in virus replication and
infextation, and it is also the major immunogenic pro-
tein that is responsible for inducing neutralizing antibo-
dies and eliciting protective immunity against
CSFV [9-12], which has been the main component in
the design of CSFV DIVA vaccines [13,14]. Previous stu-
dies shown that the N terminus of CSFV E2 has four
antigenic domains (A-D), with three subdomains (A1-
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are major neutralizing determinants [15,16]. Based on
previous study, the neutralizing epitopes corresponding
to different regions of the A or BC domains of E2 were
proposed and used as vaccines against CSFV in either
mono-or multi-peptide formulations [17-20]. Some mix-
tures of linear peptides have been reported to induce
CSFV-specific neutralizing antibodies as well as protec-
tion against CSFV challenge infection. However, in most
cases they failed to confer complete protection from
clinical signs upon viral challenge. On the other hand,
little information is available on the effect of these pep-
tide vaccines on the levels of viremia and virus
shedding [21,22].
In the present study, two commercially synthesized
peptides, which covered the antigenic domain B/C
(aa693-716) and A (aa844-865) on envelope glycoprotein
E2, induced CSFV-specific neutralizing antibodies and
provided pigs with complete or partial protection against
CSFV [21,23]. However, it was not reported that these
two new epitopes or combination epitope were
expressed by prokaryotic system or eukaryotic system to
be developed as epitope-based vaccines. Therefore, two
B-cell linear epitopes, rE2-a (CFRREKPFPHRM
DCVTTTVENED, aa844-865) and rE2-b (CKEDYR-
YAISSTNEIGLLGAGGLT, aa693-716), were constructed
and heterologously expressed in E.coli as multiple epi-
tope vaccine(MEV). The results suggested that the E.
coil-expressed epitope rE2-ba induced immunoregula-
tion, similar to that of attenuated virus vaccine(HCLV).
It is expected that the E.coli-expressed MEV may
replace the synthetic peptides and be mass produced for
inoculation of large numbers of pigs.
2. Materials and methods
2.1 Construction of recombinant expression plasmids
E2-a (aa844-865) gene and E2-b (aa693-716) gene were
amplified from the plasmid pMD18-T-E2, using two
pairs of primers 1a,2a and 1b,2b respectively (Table 1).
The amplified E2-a DNA and E2-b DNA were purified
from gel and cloned into the pMD18-T vector (Takara
Bio., Dalian, China) by the T/A cloning strategy to gen-
erate the recombinant plasmid pT-E2-a and pT-E2-b.
E2-a DNA fragment was cloned into the SacI and Hind
III sites of the plasmid pET-32a(+)(Novagen, Darmstadt,
Germany) to construct pET-E2-a. E2-b DNA fragment
was cloned into the BamH I and Sac I sites to construct
pET-E2-b. Gene E2-b and E2-a were alternately cloned
into the BamHI, SacI and HindIII sites to construct a
fusion E2-ba DNA. Three resultant constructs were veri-
fied by enzyme digestion and DNA sequencing.
2.2 Expression and purification of linear B-cell epitope in
E. coli
Recombinant protein expression was obtained in E. coli
BL21 grown at 37°C in 50 mL LB medium containing
100 μg/mL ampicillin to an OD600 of 0.6. The culture
was adjusted to 1 mM IPTG and incubated for a further
14 h. Cells were harvested by centrifugation (6 k rpm,10
min), washed twice with phosphate-buffered saline
(PBS), resuspended in PBS, and finally sonicated on ice
(8 × for 30 s). The lysate was centrifuged for 15 min at
10 k rpm at 4°C, and the polypeptide composition of
the recovered pellet and the supernatant was analyzed
by SDS-PAGE [24,25]. As the three recombinant pro-
teins appeared to be present in inclusion bodies, a
further lysis step was introduced (8 M urea overnight).
Following this, the pellet was centrifuged for 15 min at
10 k rpm at 4°C, and the supernatant was purified on
an Ni-affinity chromatography column (Amersham
Bioscience HiTrap chelating HP5 mL × 1 column). The
purification steps were performed according to the
instructions. Only freshly purified proteins were used
(with adjuvant) to injected into pigs. Protein concentra-
tion was determined by the Bradford method with BSA
(bovine serum albumin) as a standard [26].
2.3 Western blot analysis
rE2-ba, rE2-a and rE2-b proteins were treated in equal
volumes of the unreduced 2 × SDS/PAGE sample buffer
(125 mM Tris-Cl [pH 6.8], 20% glycerol, 4% SDS, 0.25%
bromophenol blue). As a reducing agent, b-mercaptoetha-
nol was added to the final concentration of 5%. Proteins
were separated by 12% SDS-PAGE and transferred by
electroblotting onto PolyScreen PVDF transfer membrane
(NEN) using semi-dry transfer cell (Bio-Rad) according to
the manufacturer’s manual [27]. The membrane was then
sequentially treated with blocking solution (PBS contain-
ing 5% non-fat skim milk), with 200-fold dilution of rabbit
hyperimmunity serum specif i ct oC S F VE 2( ag e n e r o u s
gift from Prof. Xinglong Yu, Hunan Agricultural Univer-
sity, China), and with 3,000-fold dilution of anti-rabbit IgG
goat antibody conjugated to horseradish peroxidase (Cell
Signaling TECHNOLOGY). Finally, the membrane was
soaked in DAB Reagents (Boshide Biotech Co, Wuhan,
China) for signal development.
2.4 Immunization and challenge of pigs
Twenty-five 5-week-old piglets with negative CSFV anti-
body titers, which were purchased from the Animal
Table 1 Primers used in this study
Primer Oligonucleotides (5’ -3 ’) Description
1A
2A
GTAGAGCTC(Sac I)TTCAGGAGAGACAAGC
CGCAAGCTT(Hind III)TTAATCTTCATTTTCCAC
aa844~aa865
1B
2B
CGGGGATCC(BamH I)TGCAAGGAAGATTACAG
AAAGAGCTC(Sac I)AGTGAGACCTCCCGCCC
aa693~aa716
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randomly divided into five groups of five each. The pigs
were acclimatized for 1 weeks, during which their envir-
onmental and body temperatures were measured once
daily. After acclimatization, the average temperature of
pig’s rectal was 39.0 ± 0.5°C. Group A, B and C were
repectively inoculated with purified rE2-a, rE2-b, and
rE2-ba using ISA 206 VG adjuvant(Seppic, France). The
group D was immunized with a commercial vaccine
(HCLV) as positive control and the group E was immu-
nized with PBS as negative control. The pigs were
inoculated with 500 μg of each peptide for the first and
second immunization at an interval of 2 weeks. The
immunization procedure is described by Table 2. In 3rd
week after the second immunization, all pigs were intra-
nasally inoculated (mimicking natural infection) with a
10
6 TCID50 dose of virulent CSFV Shimen strain
(obtained from the National Institute of Veterinary
Drug Control, Beijing, China; GenBank accession num-
ber: AF092448). The ambient temperature, rectal tem-
perature, symptoms (petechial hemorrhage, diarrhea and
endothelial damage) and food intake were recorded
every day during the experiment (Figure 1). Environ-
mental temperature was 24~28°C, and there was no
apparent indicator of its relationship to pig body
temperature.
2.5 Cytokine quantified by ELISA
One week after the second boost vaccination, the pre-
s e n c eo fc y t o k i n eI L - 4 ,I L - 1 0a n dI F N - g in serum sam-
ples from vaccinated pigs were determined using
commercially available swine cytokine ELISA kits (Jing-
mei Corporation, Shengzhen, China), following the man-
ufacturer’s instructions. In each assay, a control
recombinant swine cytokine was diluted over the recom-
mended detection range to generate a standard curve.
Sample concentrations were interpolated from the stan-
dard curve.
2.6 Serological examination
Serum samples from immunized pigs were collected by
jugular venipuncture every week after immunization and
post-challenge. Each sample was heated to inactivate at
56°C for 30 min and then subjected to detection by neu-
tralization peroxidase-linked assay (NPLA) [28]. All sera
duplicate and in serially two-fold dilutions and the titers
were determined as the reciprocal dilution of serum that
neutralized 100TCID50 of strain Shimen in 50% of the
culture replicates [29].
2.7 Statistical analysis
All values were expressed as the mean ± SD. The
ANOVA (F test) was used to determine the significance
of differences among the groups. P values < 0.05 were
considered statistically significant.
3. Results
3.1 Expression and Identification of multiple linear B-cell
epitopes
All the constructed plasmids were confirmed by
restricted digestion and sequencing. E. coli BL21(DE3)
cells were transformed with each recombinant plasmid,
and protein expression was induced with IPTG and ana-
lyzed by SDS-PAGE. All the expressed proteins were
predominantly found in inclusion bodies. The expressed
quantity of B-cell epitopes rE2-a, rE2-b and rE2-ba were
about 41%, 40%, and 38% of total expressed proteins in
E.coli, respectively, by densitometric scanning (Figure
2A). Complete solubilization of the inclusion bodies was
achieved in urea buffer. Then, these epitope proteins
were purified by Ni
2+-NTA resin under denaturing con-
ditions and eluted in elution buffer. After SDS-PAGE
and Coomassie brilliant blue staining, three purified pro-
teins displayed a single band with a molecular weight of
22 kDa, 22 kDa and 25 kDa, respectively. The results of
Western blot assay indicated that purified rE2-a, rE2-b
and rE2-ba were specifically recognized and strongly
r e a c t e db yC S F Vp o s i t i v es e r a( F i g u r e2 B ) .I ts u g g e s t e d
that the three linear peptides all possessed antigenicity.
3.2 Cell-mediated immune response to CSFV in
vaccinated pigs
Cellular immune response was evaluated by the produc-
tion of IFN-g, IL-4 and IL-10 induced by all vaccinated
pigs. As shown in Figure 3, the levels of IL-4 and IL-10
induced by rE2-ba were significantly higher than that of
any other groups (P < 0.05), no significant differences
were noted in the production of IL-4 and IL-10 in pigs
immunized with HCLV vaccine, rE2-b or rE2-a. The
IFN-g levels were low but uniformity stably in three
peptide vaccines, while HCLV could induce the high
level of IFN-g(P < 0.05). The levels of Th2 cytokines
response were affected in pigs vaccinated peptide
Table 2 Animal grouping and immunizing dose
Groups Pigs Protein/vaccine
name
Description Dose
A (1-5) 5 rE2-a aa844~aa865 500 μg/
swine
B (6-10) 5 rE2-b aa693~aa716 500 μg/
swine
C (11-15) 5 rE2-ba aa693~aa716
& aa844~aa865
500 μg/
swine
D (16-
20)
5 HCLV positive control 1 dose/
swine
E (21-25) 5 PBS negative
control
1 ml/swine
Twenty-five pigs were assigned randomly to five groups. Each group was
immunized by intramuscular (i.m.) injection at the midpoint of the left thigh
muscle. rE2-a, rE2-b, rE2-ba, HCLV and PBS were administrated to groups A, B,
C, D and E, respectively.
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response could not occur. Therefore, MEV could stimu-
late pigs to induce intense humoral immune response.
3.3 Antibody response in vaccinated pigs
all immunized pigs were bled weekly following primary
vaccination for determining neutralizing antibody(NA)
production induced by these epitope peptides in vitro by
NPLA assay. When the second boost vaccination, NA
begined to emerge in all of pigs immunized with MEV
or HCLV(positive controls). In the 1st week after viral
challenge, the NA titers were the most highest peak in
pigs vaccinated with peptide vaccine or HCLV and NA
titer of pigs induced by rE2-ba was much higher than
that induced by either mono-epitope peptide vaccine
(rE2-a or rE2-b) or HCLV(p < 0.05). No neutralization
activity against CSFV was determinated with serum
from PBS-immunized pigs in the whole experiment
(Table 3). These data implied that the humoral immune
response induced by the multi-epitope was better than
that induced by the mono-epitope.
3.4 Clinical signs and virus detection after CSFV challenge
infection
In the 2nd week after lethal CSFV challenge, three groups
of pigs immunized with rE2-ba, rE2-b and HCLV vaccine
returned to health, as before viral challenge, which corre-
sponded to a 100% protection rate. However, pigs immu-
nized with rE2-a only induced 80% protection and
remained infected (Table 4). The average body tempera-
ture of these four groups was in the normal range after
viral challenge (Figure 4), while all PBS-immunized pigs
in negative control group manifested obvious typical
symptoms and died during the second and third week
after viral challenge (Table 4). On postmortem examina-
tion only the PBS-immunized control and one of the
rE2-a- immunized pigs showed petechiae on the kidney.
No other pathological changes were observed
macroscopically. Samples of spleen tissue were exam-
ined for CSFV in Cell inoculation as well as in diagnos-
tic Q-PCR described by zhou et al [29]. CSFV could be
detected in the spleens of all the PBS-vaccinated and
one of the rE2-a-immunized pigs in both assays. These
results demonstrated that the multiple epitope rE2-ba
could completely protecte pigs from lethal viral chal-
lenge, similar to the conventional HCLV vaccine, and
suggest a new way to develop a epitope-based vaccine
against CSFV.
Discussion
Epitope-based vaccine is one of the promising vaccine
development strategies in the prevention of variant dis-
eases or against the different stages of some diseases. It
has serveral advantages over the conventional vaccine,
such as safety, low cost, multivalence, efficient antigen
presentation, and ease of application. On base of CSFV
glycoprotein E2, Many epitopes have been investigated
by monoclonal antibodies, phage display technique or
polypeptide synthesis.
Figure 1 Vaccination schedule and viral challenge period of in vivo experiment. Five-weeks-old pigs were acclimatized for 1 weeks and
were given a first followed by a second immunization. Pigs immunized were inoculated intranasally with a lethal dose of CSFV on day 21 after
the second immunization. Blood samples were collected once weekly from week 7. The health of each pig was assessed twice daily.
Figure 2 SDS-PAGE of recombinant proteins and Western
blotting. A: SDS-PAGE of rE2-a, rE2-b and rE2-ba. Lane 1, lysates of
the induced E. coli BL21(DE3) pET-32a(+); lane 2-4, lysates of the
induced BL21(DE3) pET-rE2-a, BL21(DE3) pET-rE2-b and BL21 (DE3)
pET-rE2-ba; lane 5, protein molecular weight markers; lane 6, lysates
of the non-induced BL21(DE3) pET-32a(+). B: Western blotting of
rE2-a, rE2-b and rE2-ba. Lane 1, protein molecular weight markers;
lane 2-4, rE2-a, rE2-b; and rE2-ba.
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specific linear epitope of CSFV E2 protein, but did not
characterize whether the epitope can induce protective
immune response [20]. Based on this core sequence, a
fusion protein was expressed to inject into pigs, but did
not produce complete protection [18], only two of five
vaccinated piglet produced significant antibody level and
survived the challenge. These results indicated that the
fusion protein containing TAVSPTTLR epitope
sequence has a certain neutralizing activity, though it is
not complete. Recently the protective immunity of two
major epitopes on CSFV E2 had been investi-
gated [21,23]. The data showed that synthetic peptide aa
693-716 (rE2-b) on CSFV E2 could induce the complete
protection in pigs against a lethal challenge of CSFV,
while synthetic peptide aa 844-865 (rE2-a) could only
induce the incomplete protection. In our study, three
peptides were expressed respectively by a prokaryotic
expression system and the antibody response induced by
multi-epitope peptide rE2-ba and mono-epitope peptide
rE2-b or rE2-a were investigated in vivo.T h er e s u l t s
indicated that all three proteins could elicit antibody
Figure 3 Cytokine response to vaccination. (A) IL-4 (pg/ml); (B) IL-10 (pg/ml); (C) IFN-g (pg/ml) expressed as the mean ± standard error. Data
shown are representative of three separate experiments. Statistically significant differences (p < 0.05) are indicated with different letters.
Table 3 Pigs immunized with rE2-a, rE2-b and rE2-ba elicited serum neutralizing antibodies early after viral challenge
Groups Pigs Inoculum Neutralizing antibody titer
day p.i. day p.c.
0
a 71 4
b 21 28 35
c 42(7) 49(14) 56(21) 63(28)
A 5 rE2-a < 2 < 2 4 16 32 32 64 64 64 64
B 5 rE2-b < 2 < 2 8 32 64 64 128 128 128 128
C 5 rE2-ba < 2 < 2 8 32 64 64 256 256 256 256
D 5 HCLV < 2 < 2 8 16 32 64 128 128 128 128
E 5 P B S <2 <2 <2 <2 <2 <2 <2 <2 <2 0
d
Antibody titers were determined using a NPLA assay, as described in the study. Samples were collected every 7 days. a, first innoculation; b, second innoculation;
c, CSFV strain Shimen challenge timepoint. d, all of the pigs in the group E had died after 28 dpc.
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similar to that of HCLV vaccine.
Prokaryotic expression systems show high expression
levels, especially for brachy-peptide such as linear B-cell
epitopes [30]. The three peptides in the present study
were short peptides, therefore, which were expressed in
a prokaryotic system induced by IPTG, and a high
expression of about 40% of total protein was obtained.
It found that more soluble protein was expressed on the
condition of 20~30°C. Accordingly, these expressed pro-
teins mought replace synthetic peptides and be mass
produced as a potential DIVA (differentiating infected
from vaccinated animals) vaccine for large numbers of
pigs.
These linear B-cell epitope peptides were expressed
with the form of a fusion protein, combined with ISA
206 VG adjuvant, and injected into pigs. They elicited a
high level of humoral immunity by NPLA assays.
Neutralizing antibodies in pigs immunized with purified
proteins were determined before and after viral chal-
lenge. Meanwhile, three weeks after the second immuni-
zation, the antibody titers of all pigs inoculated with
rE2-ba and rE2-b reached about 50% blocking rate by
IDEXX HERDCHEK* CSFV Antibody Kit (data not
shown). It suggested that antibodies induced by rE2-ba
and rE2-b provided adequate protection against CSFV.
In contrast, the antibody titers in a few pigs inoculated
with rE2-a did not exceed 40% blocking rate(data not
shown), which indicated that rE2-a provided partial
immune protection.
To understand the cytokine response to these linear
B-cell epitopes, several cytokine levels were estimated by
ELISA. The results showed that the three epitope pep-
tides led to the following changes. HCLV contained
both T-cell and B-cell epitopes that induced Th1 and
Th2 responses in vivo, so the concentration of IFN-g
Table 4 Protective potency of the expressed peptide vaccine against lethal challenge by CSFV Shimen strain
Group Vaccination Clinical sign Morbidity
(%)
Mortality
(%)
Protection
Ratio (%)
Petechial heamorrhages Diarrhea Endothelial damage
A rE2-a 1/5 1/5 1/5 20 20 80
B rE2-b 0/5 0/5 0/5 0 0 100
C rE2-ba 0/5 0/5 0/5 0 0 100
D HCLV 0/5 0/5 0/5 0 0 100
E PBS 5/5 5/5 5/5 100 100 0
Figure 4 Body temperature change (average body temperature curves of each group) of pigs after post-challenge of CSFV Shimen
strain. Body temperature was measured every day. Symbol (◆) represents the average body temperature of Group A (immunized with rE2-a).
Symbol (■) represents the average body temperature of Group B (immunized with rE2-b). Symbol (▲) represents the average body temperature
of Group C (immunized with rE2-ba). Symbol (×) represents the average body temperature of Group D (immunized with HCLV). Symbol (*)
represents the average body temperature of Group E (immunized with PBS). Obviously, the average body temperature of Groups A, B and C
waves in the normal body temperature range (39.0 ± 0.5°C) after post-challenge (dpi with CSFV Shimen strain). In contrast, the average body
temperature of Group E in the same period is 1~2°C higher. All pigs immunized with PBS died during the period from 14 to 21 dpi.
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lower than that in the pigs immunized with HCLV. In
contrast, B-cell epitope peptides induced mainly Th2-
type cytokine production. Therefore, the levels of IL-4
and IL-10 were more higher in pigs immunized with
these three peptides.
In conclusion, the immunogenic and especially protec-
tive properties of the rE2-ba protein as multiple epitope
vaccine were tested under lethal challenge conditions in
pigs. Furthermore, CSFV-specific neutralizing antibody
formation as well as the IL4/10-secreted were induced
by the E.coli-expressed epitopes, the complete protec-
tion was observed. It suggest that rE2-ba should be
developed as a new candidate epitope-based CSFV vac-
cine, by combination with two or more epitopes.
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